Cargando…

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients

OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics. The KRAS oncogene also plays an important role in the development of lung cancer. The aim of this study was to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bacchi, Carlos E., Ciol, Heloísa, Queiroga, Eduardo M., Benine, Lucimara C., Silva, Luciana H., Ojopi, Elida B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2012
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351259/ https://www.ncbi.nlm.nih.gov/pubmed/22666783 http://dx.doi.org/10.6061/clinics/2012(05)03

Ejemplares similares

Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer
por: Cavagna, Rodrigo, et al.
Publicado: (2021)

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations
por: Leal, Letícia Ferro, et al.
Publicado: (2019)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
por: Usui, Kazuhiro, et al.
Publicado: (2011)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
por: Martin, Petra, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung
por: Somaiah, Neeta, et al.
Publicado: (2014)

Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape
por: Xia, Wei, et al.
Publicado: (2019)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
por: Aran, Veronica, et al.
Publicado: (2021)

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy
por: Kim, Seung Tae, et al.
Publicado: (2013)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Akazawa, Yuki, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
por: Hsu, Chia-Hung, et al.
Publicado: (2016)

Keratinocytic epidermal nevus syndrome with Schwann cell proliferation, lipomatous tumour and mosaic KRAS mutation
por: Farschtschi, Said, et al.
Publicado: (2015)

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients
por: Gil Ferreira, Carlos, et al.
Publicado: (2014)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor
por: Machado-Rugolo, J., et al.
Publicado: (2023)

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2013)

What Is Different in the Population of the Brazilian Amazon Region so that They Have a Low Frequency of KRAS Gene Mutations?
por: de Carvalho, Luis Eduardo W., et al.
Publicado: (2017)

Adenocarcinoma of the lung with positive epidermal growth factor receptor mutation in pregnancy
por: Amanda, Gina, et al.
Publicado: (2017)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Analysis of HFE And Non-HFE Gene Mutations in Brazilian Patients with Hemochromatosis
por: Bittencourt, Paulo Lisboa, et al.
Publicado: (2009)

The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
por: Cai, Dongjing, et al.
Publicado: (2019)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
por: Elghissassi, Ibrahim, et al.
Publicado: (2014)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
por: Sutani, A, et al.
Publicado: (2006)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Realgar-induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis
por: Liu, Xiaofeng, et al.
Publicado: (2022)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
por: Said, Rabih, et al.
Publicado: (2014)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fsuad8b0fi0h4brd7ub6onhjsb